S E Monroe

No ORCID on file · 4 papers in corpus
article 1995
Effects of a gonadotropin-releasing hormone agonist on the calcium-parathyroid axis and bone turnover in women with endometriosis
American Journal of Obstetrics and Gynecology ·doi:10.1016/0002-9378(95)90348-8

ObjectiveOur purpose was to investigate the effects of nafarelin on bone turnover and mass (bone mineral density, in grams per square centimeter) in women with endometriosis.Study designWe monitored 22 young women with endometriosis during …

article 1990
Nafarelin: a new medical therapy for endometriosis.
Progress in clinical and biological research
article 1985
Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin)
Fertility and Sterility ·doi:10.1016/s0015-0282(16)48970-3

Administration of superactive agonistic analogs of gonadotropin-releasing hormone (GnRH) has been shown to induce a paradoxic and reversible suppression of gonadotropins, resulting in suppressed gonadal steroid concentrations. Because there…

other 1984
Stimulation of LH fragments with reduced bioactivity following GnRH agonist administration in women
The Journal of clinical endocrinology and metabolism ·doi:10.1210/jcem-58-4-755

In eumenorrheic women with endometriosis and in oligo-amenorrheic women with polycystic ovarian disease (PCO), chronic administration of a long-acting GnRH agonist (GnRH-a) reduced the circulating concentrations of estrogens and androgens t…